Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Orion Corp (ORNBV) Ser B NPV

Sell:€39.53 Buy:€39.56 Change: €0.39 (0.98%)
Market closed |  Prices as at close on 5 December 2019 | Switch to live prices |
Sell:€39.53
Buy:€39.56
Change: €0.39 (0.98%)
Market closed |  Prices as at close on 5 December 2019 | Switch to live prices |
Sell:€39.53
Buy:€39.56
Change: €0.39 (0.98%)
Market closed |  Prices as at close on 5 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Orion Oyj is a Finland-based company engaged in the development, manufacture and marketing of pharmaceuticals and diagnostic tests. The Company operates, along with its subsidiaries, in two business segments: the Pharmaceuticals business segment develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients, and the Diagnostics business segment develops, manufactures and markets diagnostic tests. The Company’s business comprises two main divisions: Proprietary Products and Specialty Products. Its Proprietary Products consist of patented prescription products in three therapy areas: central nervous system diseases, oncology and critical care, and Easyhaler pulmonary drugs. The Company’s Specialty Products, which include the provision of generic prescription drugs and self-care products for basic healthcare. In addition the Company also produces veterinary medicines for pets and production animals.

Contact details

Address:
Orionintie 1A
ESPOO
02200
Finland
Telephone:
+358 (10) 4261
Website:
www.orion.fi

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ORNBV
ISIN:
FI0009014377
Market cap:
€5.64 billion
Shares in issue:
140.49 million
Sector:
Pharmaceuticals
Exchange:
Helsinki Stock Exchange
Country:
Finland
Currency:
Euro
Indices:
OMX Helsinki 25

Key personnel

  • Heikki Westerlund
    Independent Chairman of the Board
  • Timo Lappalainen
    President, Chief Executive Officer, Chairman of the Executive Management Board
  • Timo Maasilta
    Independent Vice Chairman of the Board
  • Jari Karlson
    Chief Financial Officer; Senior Vice President, Animal Health; Member of the Executive Management Board
  • Satu Ahomaki
    Senior Vice President, Commercial Operations; Member of the Executive Management Board
  • Markku Huhta-Koivisto
    Senior Vice President, Growth Projects; Member of the Executive Management Board
  • Liisa Hurme
    Senior Vice President, Supply Chain and Chairman of the Board of Fermion Oy; Member of the Executive Management Board
  • Virve Laitinen
    Senior Vice President, Specialty Products; Member of the Executive Management Board
  • Christer Nordstedt
    Senior Vice President, Research and Development; Member of the Executive Management Board
  • Olli Huotari
    Senior Vice President, Corporate Functions; Member of the Executive Management Board; Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.